# Serum Institute of India

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/serum-institute-of-india
Canonical HTML page: https://getyourbrief.com/entity/serum-institute-of-india

## Timeline

- **2026-07-14**: First-in-Human Trial Begins — A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
- **2026-05-18**: WHO Declares Public Health Emergency — The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.

## Recent coverage (2 stories, network-wide)

### Meiji Licenses JE Vaccine Tech to Serum Institute for 2027 Filing
2026-08-24 09:41:38 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Full story: https://getbiobrief.com/story/meiji-serum-je-vaccine-tech-transfer-bio

### First Human Trial of Bundibugyo Ebola Vaccine Begins as Death Toll Tops 700
2026-07-20 14:14:43 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Full story: https://gethealthbrief.com/story/first-human-trial-bundibugyo-ebola-vaccine-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.